SG11202101014XA - Chimeric antigen receptor therapy t cell expansion kinetics and uses thereof - Google Patents
Chimeric antigen receptor therapy t cell expansion kinetics and uses thereofInfo
- Publication number
- SG11202101014XA SG11202101014XA SG11202101014XA SG11202101014XA SG11202101014XA SG 11202101014X A SG11202101014X A SG 11202101014XA SG 11202101014X A SG11202101014X A SG 11202101014XA SG 11202101014X A SG11202101014X A SG 11202101014XA SG 11202101014X A SG11202101014X A SG 11202101014XA
- Authority
- SG
- Singapore
- Prior art keywords
- antigen receptor
- chimeric antigen
- cell expansion
- receptor therapy
- expansion kinetics
- Prior art date
Links
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 title 1
- 230000010261 cell growth Effects 0.000 title 1
- 238000002560 therapeutic procedure Methods 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464411—Immunoglobulin superfamily
- A61K39/464412—CD19 or B4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57426—Specifically defined cancers leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5156—Animal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2302—Interleukin-2 (IL-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biotechnology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Developmental Biology & Embryology (AREA)
- General Chemical & Material Sciences (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862713994P | 2018-08-02 | 2018-08-02 | |
| US201862756391P | 2018-11-06 | 2018-11-06 | |
| PCT/US2019/044638 WO2020028647A1 (en) | 2018-08-02 | 2019-08-01 | Chimeric antigen receptor therapy t cell expansion kinetics and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202101014XA true SG11202101014XA (en) | 2021-02-25 |
Family
ID=67770563
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202101014XA SG11202101014XA (en) | 2018-08-02 | 2019-08-01 | Chimeric antigen receptor therapy t cell expansion kinetics and uses thereof |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20200038442A1 (en) |
| EP (1) | EP3830125A1 (en) |
| JP (2) | JP2021531813A (en) |
| KR (2) | KR20210038922A (en) |
| CN (1) | CN112533953A (en) |
| AU (2) | AU2019314452B2 (en) |
| CA (2) | CA3170491A1 (en) |
| IL (2) | IL280329B2 (en) |
| SG (1) | SG11202101014XA (en) |
| TW (2) | TW202216175A (en) |
| WO (1) | WO2020028647A1 (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021168376A1 (en) * | 2020-02-20 | 2021-08-26 | Kite Pharma, Inc. | Chimeric antigen receptor t cell therapy |
| AU2022362872A1 (en) * | 2021-10-15 | 2024-05-16 | Astrazeneca Ab | Anti-steap2 chimeric antigen receptors and uses thereof |
| CN118742810A (en) * | 2022-02-15 | 2024-10-01 | 凯德药业股份有限公司 | Predicting adverse events from immunotherapy |
| WO2024092145A1 (en) * | 2022-10-28 | 2024-05-02 | Kite Pharma, Inc. | Expedited administration of engineered lymphocytes |
| WO2024123872A1 (en) * | 2022-12-07 | 2024-06-13 | The Board Of Regents Of The University Of Texas System | Prediction and treatment of immunotherapy toxicity |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5728388A (en) | 1989-10-03 | 1998-03-17 | Terman; David S. | Method of cancer treatment |
| US6319494B1 (en) | 1990-12-14 | 2001-11-20 | Cell Genesys, Inc. | Chimeric chains for receptor-associated signal transduction pathways |
| IL104570A0 (en) | 1992-03-18 | 1993-05-13 | Yeda Res & Dev | Chimeric genes and cells transformed therewith |
| US5827642A (en) | 1994-08-31 | 1998-10-27 | Fred Hutchinson Cancer Research Center | Rapid expansion method ("REM") for in vitro propagation of T lymphocytes |
| US6406699B1 (en) | 1999-10-05 | 2002-06-18 | Gary W. Wood | Composition and method of cancer antigen immunotherapy |
| US6867041B2 (en) | 2000-02-24 | 2005-03-15 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| US6797514B2 (en) | 2000-02-24 | 2004-09-28 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| IL151287A0 (en) | 2000-02-24 | 2003-04-10 | Xcyte Therapies Inc | A method for stimulation and concentrating cells |
| GB0700058D0 (en) | 2007-01-03 | 2007-02-07 | Scancell Aps | Anti-tumor vaccine based on normal cells |
| SG190997A1 (en) | 2010-12-09 | 2013-07-31 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| SG192010A1 (en) | 2011-01-18 | 2013-08-30 | Univ Pennsylvania | Compositions and methods for treating cancer |
| CN106074601A (en) | 2011-03-23 | 2016-11-09 | 弗雷德哈钦森癌症研究中心 | Method and composition for cellular immunotherapy |
| EP2532740A1 (en) | 2011-06-11 | 2012-12-12 | Michael Schmück | Antigen-specific CD4+ and CD8+ central-memory T cell preparations for adoptive T cell therapy |
| SG11201400527XA (en) | 2011-09-16 | 2014-04-28 | Univ Pennsylvania | Rna engineered t cells for the treatment of cancer |
| WO2014055657A1 (en) | 2012-10-05 | 2014-04-10 | The Trustees Of The University Of Pennsylvania | Use of a trans-signaling approach in chimeric antigen receptors |
| IL290744B2 (en) * | 2014-02-04 | 2024-10-01 | Kite Pharma Inc | Methods for producing autologous t cells useful to treat b cell malignancies and other cancers and compositions thereof |
| EP3811970A1 (en) * | 2014-03-15 | 2021-04-28 | Novartis AG | Regulatable chimeric antigen receptor |
| US10689456B2 (en) * | 2014-12-08 | 2020-06-23 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-CD70 chimeric antigen receptors |
| US10647778B2 (en) * | 2015-02-09 | 2020-05-12 | University Of Florida Research Foundation, Incorporated | Bi-specific chimeric antigen receptor and uses thereof |
| EP3283083A4 (en) * | 2015-04-15 | 2018-10-31 | Prospect Chartercare RWMC LLC D/B/A Roger Williams Medical Center | Hepatic arterial infusion of car-t cells |
| CN109476722A (en) * | 2015-07-21 | 2019-03-15 | 诺华股份有限公司 | The method of the effect of for improving immunocyte and expansion |
| US11541076B2 (en) * | 2017-01-13 | 2023-01-03 | Celdara Medical, Llc | Chimeric antigen receptors targeting TIM-1 |
-
2019
- 2019-08-01 CN CN201980051623.2A patent/CN112533953A/en active Pending
- 2019-08-01 EP EP19759453.4A patent/EP3830125A1/en active Pending
- 2019-08-01 KR KR1020217005607A patent/KR20210038922A/en not_active IP Right Cessation
- 2019-08-01 US US16/529,081 patent/US20200038442A1/en active Pending
- 2019-08-01 IL IL280329A patent/IL280329B2/en unknown
- 2019-08-01 CA CA3170491A patent/CA3170491A1/en active Pending
- 2019-08-01 CA CA3107938A patent/CA3107938C/en active Active
- 2019-08-01 AU AU2019314452A patent/AU2019314452B2/en active Active
- 2019-08-01 KR KR1020247019878A patent/KR20240103033A/en active Search and Examination
- 2019-08-01 SG SG11202101014XA patent/SG11202101014XA/en unknown
- 2019-08-01 IL IL311860A patent/IL311860A/en unknown
- 2019-08-01 WO PCT/US2019/044638 patent/WO2020028647A1/en unknown
- 2019-08-01 JP JP2021505310A patent/JP2021531813A/en active Pending
- 2019-08-02 TW TW110134283A patent/TW202216175A/en unknown
- 2019-08-02 TW TW108127613A patent/TWI807077B/en active
-
2023
- 2023-03-02 AU AU2023201286A patent/AU2023201286A1/en active Pending
- 2023-11-08 JP JP2023190807A patent/JP2024016200A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2020028647A1 (en) | 2020-02-06 |
| CN112533953A (en) | 2021-03-19 |
| IL280329B2 (en) | 2024-09-01 |
| IL280329A (en) | 2021-03-01 |
| IL280329B1 (en) | 2024-05-01 |
| TW202216175A (en) | 2022-05-01 |
| CA3170491A1 (en) | 2020-02-06 |
| CA3107938A1 (en) | 2020-02-06 |
| AU2019314452B2 (en) | 2022-12-08 |
| AU2023201286A1 (en) | 2023-04-06 |
| IL311860A (en) | 2024-06-01 |
| TWI807077B (en) | 2023-07-01 |
| EP3830125A1 (en) | 2021-06-09 |
| US20200038442A1 (en) | 2020-02-06 |
| KR20210038922A (en) | 2021-04-08 |
| TW202019445A (en) | 2020-06-01 |
| AU2019314452A1 (en) | 2021-02-18 |
| KR20240103033A (en) | 2024-07-03 |
| JP2021531813A (en) | 2021-11-25 |
| CA3107938C (en) | 2024-04-30 |
| JP2024016200A (en) | 2024-02-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL280329A (en) | Chimeric antigen receptor therapy t cell expansion kinetics and uses thereof | |
| IL274921A (en) | Bcma-targeting chimeric antigen receptor, and uses thereof | |
| IL280718A (en) | T cell receptor constructs and uses thereof | |
| IL274617A (en) | Bcma-targeting chimeric antigen receptor, cd19-targeting chimeric antigen receptor, and combination therapies | |
| EP3630980A4 (en) | Chimeric antigen receptor cell preparation and uses thereof | |
| SG10202012157QA (en) | Chimeric antigen receptor and car-t cells that bind bcma | |
| IL279063A (en) | Chimeric antigen receptor t cells (car-t) for the treatment of cancer | |
| EP3564266A4 (en) | Novel chimeric antigen receptor and use thereof | |
| ZA202000852B (en) | T cell receptor-deficient chimeric antigen receptor t-cells and methods of use thereof | |
| IL280029A (en) | Ror-1 specific chimeric antigen receptors and uses thereof | |
| IL281232A (en) | Chimeric antigen receptor for solid cancer and t cells expressing chimeric antigen receptor | |
| EP4166566A4 (en) | Chimeric antigen receptor and use thereof | |
| SG11202010642TA (en) | Combination therapy of a chimeric antigen receptor (car) t cell therapy and a kinase inhibitor | |
| SG11202101169PA (en) | Chimeric antigen receptor that binds hla-dr and car-t cell | |
| EP4054603A4 (en) | Chimeric antigen receptor t cell therapy | |
| EP3827025A4 (en) | Gd2-based chimeric antigen receptor and application thereof | |
| EP3733839A4 (en) | Antibody-modified chimeric antigen receptor modified t cell and uses thereof | |
| EP3573660A4 (en) | Improved antibody-coupled t cell receptor constructs and therapeutic uses thereof | |
| ZA201906321B (en) | Chimeric antigen receptor | |
| EP4039712A4 (en) | Cll1-targeting chimeric antigen receptor and application thereof | |
| IL308227A (en) | Chimeric antigen receptor t cell therapy | |
| IL281428A (en) | Chimeric antigen receptor | |
| SG11202001011XA (en) | Chimeric antigen receptor and car-t cells that bind cxcr5 | |
| GB201709508D0 (en) | Chimeric antigen receptor | |
| GB2585607B (en) | Chimeric antigen receptor and application thereof |